MCU Inhibitor Ruthenium Red Alleviates the Osteoclastogenesis and Ovariectomized Osteoporosis via Suppressing RANKL‐Induced ROS Production and NFATc1 Activation through P38 MAPK Signaling Pathway
Open Access
- 13 September 2022
- journal article
- research article
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2022 (1) , 7727006
Abstract
Osteoporosis is a disorder of bone metabolism that is extremely common in elderly patients as well as in postmenopausal women. The main manifestation is that the bone resorption capacity is greater than the bone formation capacity, which eventually leads to a decrease in bone mass, increasing the risk of fracture. There is growing evidence that inhibiting osteoclast formation and resorption ability can be effective in treating and preventing the occurrence of osteoporosis. Our study is the first time to explore the role of the mitochondrial calcium uniporter (MCU) and its inhibitor ruthenium red (RR) in bone metabolism, clarifying the specific mechanism by which it inhibits osteoclast formation in vitro and plays a therapeutic role in osteoporosis in vivo. We verified the suppressive effects of RR on the receptor activator of nuclear factor‐κB ligand (RANKL‐)‐induced differentiation and bone resorption function of osteoclasts in vitro. The reactive oxygen species (ROS) production stimulated by RANKL and the expression level of P38 MAPK/NFATc1 were also found to be inhibited by RR. Moreover, the promotion of RR on osteogenesis differentiation was investigated by alkaline phosphatase (ALP) and alizarin red S (ARS) staining and the detection of osteogenesis‐specific gene expression levels by quantitative polymerase chain reaction (qPCR) and western blotting. Moreover, in ovariectomy (OVX‐)‐induced osteoporosis models, RR can downregulate the expression and function of the MCU, relieving bone loss and promoting osteogenesis to present a therapeutic effect on osteoporosis. This new finding will provide an important direction for the study of RR and MCU in the study of bone metabolism therapy targets.Keywords
Funding Information
- Natural Science Foundation of Zhejiang Province in China (LGF22H060003)
This publication has 52 references indexed in Scilit:
- Integrative genomics identifies MCU as an essential component of the mitochondrial calcium uniporterNature, 2011
- A forty-kilodalton protein of the inner membrane is the mitochondrial calcium uniporterNature, 2011
- Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone lossClinical Interventions in Aging, 2010
- RANKL-mediated Reactive Oxygen Species Pathway That Induces Long Lasting Ca2+ Oscillations Essential for OsteoclastogenesisJournal of Biological Chemistry, 2010
- NFATc1 in mice represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in cherubismJournal of Clinical Investigation, 2008
- Ru360, a specific mitochondrial calcium uptake inhibitor, improves cardiac post‐ischaemic functional recovery in rats in vivoBritish Journal of Pharmacology, 2006
- Mitochondrial calcium signalling and cell death: Approaches for assessing the role of mitochondrial Ca2+ uptake in apoptosisCell Calcium, 2006
- The mitochondrial calcium uniporter is a highly selective ion channelNature, 2004
- Osteoclast differentiation and activationNature, 2003
- Pharmacokinetics of AlendronateClinical Pharmacokinetics, 1999